Document Detail

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
MedLine Citation:
PMID:  18156144     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The aim of this study was to evaluate the activity and toxicity of pemetrexed and carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma (MPM). PATIENTS AND METHODS: Patients with measurable advanced MPM and a zero to two Eastern Cooperative Oncology Group (ECOG) performance status (PS) were enrolled. The schedule was pemetrexed 500 mg/m(2) in combination with carboplatin area under the curve 5, every 21 days. In all, 76 patients were treated. Median age was 65 years; median ECOG PS was zero. RESULTS: Grade 3 hematological toxicity according to World Health Organization criteria was seen in 36 (47.3%) patients; grade 4 hematological toxicity in 5 (6.5%) patients. There were 16 (21%) partial responses and 3 (4%) complete responses, for an overall response rate of 19 (25%) [95% confidence interval (CI) 15.3-34.7]. In all, 29 (39%) (95% CI 28-48) patients reported stable disease. The median survival was estimated at 14 months. CONCLUSION: This combination of carboplatin and pemetrexed is moderately active and the toxicity is acceptable.
B Castagneto; M Botta; E Aitini; F Spigno; D Degiovanni; O Alabiso; M Serra; A Muzio; R Carbone; R Buosi; V Galbusera; E Piccolini; L Giaretto; L Rebella; M Mencoboni
Related Documents :
9164194 - Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etopos...
9020284 - Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lun...
25487524 - Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer af...
21774104 - Tumor volume as a potential imaging-based risk-stratification factor in trimodality the...
2206854 - A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childho...
4080634 - Prognosis in colorectal carcinoma. a reassessment of the pathologist's role.
Publication Detail:
Type:  Clinical Trial, Phase II; Historical Article; Journal Article     Date:  2007-12-20
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  19     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-04     Completed Date:  2008-03-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  370-3     Citation Subset:  IM    
Department of Oncology, Novi Ligure Hospital, viale Giolitti, Novi Ligure (AL), Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carboplatin / administration & dosage*,  adverse effects
Confidence Intervals
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Follow-Up Studies
Glutamates / administration & dosage*,  adverse effects
Guanine / administration & dosage,  adverse effects,  analogs & derivatives*
History, Ancient
Kaplan-Meiers Estimate
Maximum Tolerated Dose
Mesothelioma / drug therapy*,  mortality,  pathology*
Middle Aged
Neoplasm Staging
Pleural Neoplasms / drug therapy*,  mortality,  pathology*
Risk Assessment
Survival Analysis
Treatment Outcome
Reg. No./Substance:
0/Glutamates; 137281-23-3/pemetrexed; 41575-94-4/Carboplatin; 73-40-5/Guanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the...
Next Document:  Nonadditive effects of PAHs on Early Vertebrate Development: mechanisms and implications for risk as...